Equities
Health CarePharmaceuticals & Biotechnology
  • Price (USD)2.18
  • Today's Change0.00 / 0.00%
  • Shares traded1.33m
  • 1 Year change1.73%
  • Beta1.1463
Data delayed at least 15 minutes, as of Oct 29 2020 20:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

PDL BioPharma, Inc. has a portfolio of income generating assets based on alternative financings. These alternative financings fall into one of three categories: royalty monetization, debt structures and hybrids of the two. The Company's investments are typically in assets with strong intellectual property protection and are commercial stage or soon-to-be approved. The counterparties in these transactions can be biotechs, pharmas, medtech companies, universities and inventors.

  • Revenue in USD (TTM)51.81m
  • Net income in USD-85.65m
  • Incorporated1986
  • Employees75.00
  • Location
    PDL BioPharma Inc932 Southwood BlvdINCLINE VILLAGE 89451United StatesUSA
  • Phone+1 (775) 832-8500
  • Fax+1 (775) 832-8501
  • Websitehttp://www.pdl.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Apyx Medical Corp25.33m-16.76m206.32m266.00--3.00--7.92-0.4893-0.48930.74031.950.30391.574.0595,229.32-20.10-24.69-22.47-28.3463.8558.40-66.16-65.616.70--0.0121--70.040.3971-82.73--15.61--
Misonix Inc62.48m-17.42m213.01m125.00--1.37--3.22-1.04-1.043.988.440.53461.767.61---14.90-14.47-16.70-16.6669.9570.28-27.88-18.062.93-6.960.2296--60.8422.99-135.80------
Sientra Inc75.00m-105.57m219.36m133.00--9.83--2.90-2.12-2.121.510.43930.34790.82093.10221,244.80-48.97-43.69-72.12-62.6658.5862.97-140.75-121.481.95-2.790.742--22.8613.35-29.28--56.12--
Scpharmaceuticals Inc0.00-32.41m235.50m15.00--2.32-----1.62-1.620.003.590.00----0.00-31.26---34.49-------------22.710.1629-------12.07------
TELA Bio Inc16.07m-27.50m236.10m89.00--3.58--14.14-2.41-2.411.414.400.25881.367.17180,561.80-39.46---43.40--61.31---152.45--24.71-6.080.325--86.68---0.9794------
iCAD Inc29.36m-20.51m240.00m135.00--8.55--7.72-1.02-1.021.451.160.6632.594.34217,451.90-46.33-27.53-67.35-41.2775.2471.72-69.88-39.402.53-1.010.2076--22.32-6.53-50.28---24.70--
Invacare Corporation883.43m-42.61m247.09m3.90k--0.819--0.2801-1.25-1.2526.068.781.014.628.12226,519.80-4.86-5.33-6.65-7.0828.8927.60-4.82-4.850.87720.35470.4853---4.56-6.09-16.07---2.480.00
Stereotaxis Inc26.20m-6.34m249.08m118.00--6.65--9.09-0.0909-0.09090.38270.56640.66911.836.52222,002.30-12.60-22.38-19.09--78.5774.52-18.83-14.453.51--0.0496---1.51-3.76-357.07---24.96--
PDL BioPharma Inc51.81m-85.65m254.18m75.00--0.5908--4.80-0.7269-1.310.44553.690.07343.493.31690,786.70-12.256.98-12.937.772.74---166.7926.1713.33--0.031231.21-72.36-37.65-2.25---50.29--
United Health Products Inc430.00-4.45m254.95m5.00------549,677.40-0.025-0.0250.00-0.00450.0010.0112--86.00-1,078.17-2,478.42-----130.2347.90-1,035,044.00-3,202.840.025-11.62-----85.87-50.31-22.21------
Repro-Med Systems, Inc.26.88m-55.06k262.14m71.00--6.49856.029.48-0.0008-0.00080.6760.8940.90413.168.59378,569.60-0.1852---0.2234--63.35---0.2049--5.02--0.082--33.47---38.02------
Retractable Technologies, Inc.47.04m6.28m264.96m140.0039.957.7535.405.360.1910.1911.441.011.133.786.44336,034.9016.74-0.564621.67-0.722933.8432.7014.83-0.66312.29--0.1049--25.613.90219.59---8.91--
InfuSystem Holdings Inc90.75m5.66m270.85m269.0050.7810.2314.032.960.26210.26214.321.301.1610.546.52337,364.307.24-0.21719.79-0.268459.3164.546.24-0.24360.92224.440.6093--20.824.06224.29-16.5218.41--
Iradimed Corp36.33m5.35m275.46m114.0051.074.5940.777.400.42980.42982.964.780.57811.957.00318,650.708.5215.459.2717.0675.2678.4814.7420.2710.51--0.000.0026.5419.7352.7936.26-4.33--
Accuray Incorporated382.93m3.83m279.07m932.0068.974.0022.460.66450.04050.04054.250.69790.82431.833.78410,866.900.8238-1.571.38-3.0039.1038.920.9994-1.721.220.57980.7484---8.560.1641123.29---18.62--
Oxford Immunotec Global PLC59.08m-15.35m304.98m260.00--1.54--4.94-0.5915-0.63952.247.280.26341.356.40243,123.50-6.84-6.11-7.29-6.8973.8866.23-25.98-15.6816.10--0.00--23.368.29-110.72---11.27--
Data as of Oct 29 2020. Currency figures normalised to PDL BioPharma Inc's reporting currency: US Dollar USD

Institutional shareholders

55.51%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 30 Jun 20209.60m8.43%
Park West Asset Management LLCas of 01 Oct 20209.17m8.05%
BlackRock Fund Advisorsas of 30 Jun 20209.04m7.94%
Renaissance Technologies LLCas of 30 Jun 20208.29m7.28%
SSgA Funds Management, Inc.as of 30 Jun 20205.97m5.24%
The Vanguard Group, Inc.as of 30 Jun 20205.73m5.02%
Brandes Investment Partners LPas of 30 Jun 20205.35m4.70%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 20204.46m3.91%
Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 20202.97m2.61%
Engine Capital Management LPas of 30 Jun 20202.68m2.35%
More ▼
Data from 30 Jun 2020 - 30 Jun 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.